We generated a comprehensive database, encompassing clinical, demographic, behavioral, and molecular data, enabling the identification of specific patterns. Noteworthy achievements include circadian rhythm analyses, creation of an annotated Spanish corpus. Especifically, we produced machine learning models predicting relapse in early-stage non small cell lung cancer patients with automatic explanations, fostering personalized and reproducible predictions. CLARIFY Platform was fully operational enhancing medical decisions during and after treatment, thus enabling clinicians to detect deteriorating health factors and implement personalized interventions through wearable devices and quality of life questionnaires. Therefore, CLARIFY Platform emerges as a groundbreaking decision support system, meeting clinicians' needs and enhancing healthcare accuracy, efficiency, and accessibility for cancer patients. Through personalized follow-ups based on risk factors, the Platform significantly contributes to improving the quality of life and well-being of long-term cancer survivors. These activities aligned at all times the Artificial Intelligence component with ethical standards, contributing to EU policy initiatives. The knowledge generated produced 35 publications, 20 scientific articles and 15 international presentations, and facilitated academic training.